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Abstract
Vascular Endothelial Growth Factor (VEGF) can induce normal or aberrant angiogenesis depending on the amount secreted in the microenviron-
ment around each cell. Towards a possible clinical translation, we developed a Fluorescence Activated Cell Sorting (FACS)-based technique to
rapidly purify transduced progenitors that homogeneously express a desired specific VEGF level from heterogeneous primary populations. Here,
we sought to induce safe and functional angiogenesis in ischaemic myocardium by cell-based expression of controlled VEGF levels. Human adi-
pose stromal cells (ASC) were transduced with retroviral vectors and FACS purified to generate two populations producing similar total VEGF
doses, but with different distributions: one with cells homogeneously producing a specific VEGF level (SPEC), and one with cells heteroge-
neously producing widespread VEGF levels (ALL), but with an average similar to that of the SPEC population. A total of 70 nude rats underwent
myocardial infarction by coronary artery ligation and 2 weeks later VEGF-expressing or control cells, or saline were injected at the infarction
border. Four weeks later, ventricular ejection fraction was significantly worsened with all treatments except for SPEC cells. Further, only SPEC
cells significantly increased the density of homogeneously normal and mature microvascular networks. This was accompanied by a positive
remodelling effect, with significantly reduced fibrosis in the infarcted area. We conclude that controlled homogeneous VEGF delivery by FACS-
purified transduced ASC is a promising strategy to achieve safe and functional angiogenesis in myocardial ischaemia.
Keywords: myocardial infarction adipose stem cells Vascular Endothelial Growth Factor angiogenesis cell therapy
Introduction
Ischaemic heart pathologies are caused by inadequate balance
between myocardial oxygen supply and demand such as in ang-
ina or myocardial infarction. Percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG) typically
restore the macrovascularization in the ischaemic area of the
either acutely or chronically affected myocardium. But many
patients could also benefit from additional therapeutic angio-
genic strategies that would improve the microvascularization [1].
VEGF is the master regulator of angiogenesis [2], but it can also
induce aberrant and dysfunctional vascular growth if its expression is
not tightly controlled [3, 4]. We previously found that, as VEGF binds
tightly to extracellular matrix, the induction of normal or aberrant
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angiogenesis depends strictly on its amount localized in the microen-
vironment around each producing cell and not simply on the total
dose delivered [5, 6]. This finding helps explaining the apparently nar-
row therapeutic window for VEGF gene therapy and its lack of efficacy
at safe vector doses in first-generation clinical trials for therapeutic
angiogenesis [7]. In these trials, only the total dose of vector could be
controlled, but not the level of expression achieved in individual cells,
leading to a heterogeneous and unpredictable distribution of VEGF
within the tissue [8].
To overcome this limitation and the ensuing loss of therapeutic
potential, we previously developed a high-throughput, FACS-based
technology to identify and rapidly purify cells expressing a specific
desired VEGF level from a heterogeneous population of transduced
progenitors. This was achieved using a retroviral construct expressing
the VEGF sequence quantitatively linked through an internal ribosome
entry site (IRES) to a FACS-quantifiable syngenic cell surface marker
(truncated CD8a) so that the amount of CD8 on the cell surface would
reflect the level of secreted VEGF [9]. Populations of so-purified
VEGF-expressing primary myoblasts could ensure robust, normal and
stable angiogenesis both in normal [9] and chronically ischaemic [10]
skeletal muscle, while angioma growth was completely avoided. How-
ever, skeletal myoblasts are not suitable for cardiac cell therapy,
because of their inability to electrically couple and integrate with the
surrounding cardiomyocytes, leading to fatal arrhythmias [11]. On the
other hand, adipose tissue-derived stromal cells (ASC) possess sev-
eral desirable features for cell therapy approaches to cardiac repair
[12]. In fact, ASC (i) can be easily obtained in large quantities from
autologous liposuction material [13], (ii) have differentiation potential
into cardiomyocytes [14] and (iii) have been reported to reduce the
infarct area [15] and to significantly improve the left ventricular ejec-
tion fraction [16], as well as the electrophysiological function after
delivery in animal models of myocardial infarction [12]. Recently, we
have shown that injection of genetically engineered VEGF-expressing
human ASC in normal myocardium, FACS purified to homogeneously
produce a specific controlled and safe level of VEGF, could induce
normal and stable angiogenesis while completely preventing aberrant
vascular growth [17].
In this study, we tested the hypothesis that delivery of human
ASC FACS purified to express controlled VEGF levels at the infarct
border zone could efficiently induce safe angiogenesis and ultimately
improve cardiac function in a rat model of myocardial infarction.
Materials & methods
Cell culture
Human adipose tissue was obtained from three healthy patients under-
going plastic surgery after informed consent and according to a proto-
col approved by the Ethical Committee of the Basel University Hospital.
All investigations conformed to the Declaration of Helsinki. Tissue was
minced and digested with 0.15% collagenase (Worthington Biochemical
Corporation, Lakewood, NJ) in phosphate-buffered saline (PBS) at 37°C
under continuous shaking for 60 min. After centrifugation at 1500 rpm
for 10 min, the lipid-rich layer was discarded and the cellular pellet was
washed once with PBS. Released cells were strained through a 100-lm
nylon-mesh followed by a 70-lm nylon-mesh to remove fibrous debris,
plated at a density of 105 cells/cm2 and cultured in high-glucose Dul-
becco’s modified Eagle’s medium with 10% foetal bovine serum, as
described [18]. After 4 days, cells were retrovirally transduced twice a
day according to a recently optimized high-efficiency protocol [19] for a
total of six rounds. The retroviral vectors expressing rat VEGF164 and
truncated rat CD8a have been previously described [10]. We have previ-
ously found that neither the transduction procedure nor VEGF expres-
sion affected the surface marker expression profile, proliferative ability
and multi-lineage differentiation potential of the transduced ASC [19].
After 12 days, (approximately 90% confluence), cells were FACS-sorted
with a BD Influx Cell Sorter (BD Biosciences, Basel, Switzerland) to gen-
erate the three different treatment groups (CD8, ALL and SPEC),
according to a previously published protocol [9, 17]. Briefly at the first
passage, control cells, which were transduced with the control virus
expressing CD8 alone, were FACS purified to eliminate the few non-
transduced cells and yield a purely CD8-positive population (CD8). Part
of the cells transduced with the virus containing VEGF were FACS puri-
fied through a specific narrow gate to produce a homogeneous cell
population expressing a specific moderate VEGF level (SPEC) and the
rest of the cells were sorted to generate a population expressing all the
heterogeneous VEGF levels (ALL).
VEGF ELISA measurements
The production of rat VEGF164 and human VEGF165 was quantified as
previously described [17]. Briefly, species-specific Quantikine VEGF
ELISA kits (R&D Systems, Abingdon, UK) were used according to man-
ufacturer’s protocol. One millilitre of medium was harvested from ASC
cultured in a 60-mm dish, following 4 hrs of incubation, filtered and
analysed in duplicate. Results were normalized by the number of cells
and time of incubation and expressed as ng of VEGF/106 cells/day. Four
separate dishes of cells were assayed for each cell type from three
independent donors.
Animals
All animals were treated in compliance with Swiss Federal guidelines for
animal welfare and all procedures were approved by the Veterinary
Office of the Canton Bern (Bern, Switzerland) and conform to the Direc-
tive 2010/63/EU of the European Parliament. Immunodeficient male
nude rats (Hsd: RH-rnu/rnu, Harlan, Venray, Netherlands) were used to
prevent rejection of human ASC.
Myocardial infarction and in vivo cell
implantation
Anaesthesia was performed with isoflurane (5% of oxygen for induction
and 2.5% for maintenance) and additional buprenorphine (10 mg/kg).
Animals were placed on a warming pad (37°C) and intubated with a
14G tracheal cannula (Abbocath, Abbott, Sligo, Ireland) and ventilated at
80 cycles/min (Small Animal Ventilator 683, Harvard Apparatus, Inc.,
Holliston, MA, USA). Hearts were exposed through a left thoracotomy
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[20]. After opening the pericardium, a myocardial infarction was created
by a permanent ligation of the left anterior descending (LAD) coronary
artery using a 7/0 polypropylene suture. Distal ligature allowed the
induction of an initial small infarct with limited mechanical overload and
consequently reduced animal mortality over the study period. Two
weeks after coronary ligation, a pre-treatment echocardiography (E1)
was performed to exclude animals with an ejection fraction above 60%
(i.e. with no significant infarction) or under 45% (i.e. already close to
heart failure), before randomization to one of the four treatment groups.
Animals received five direct intramyocardial injections into the anterior
wall around the infarction for a total of 150 ll of either PBS alone or
containing 107 cells for each of the three selected conditions (CD8, ALL
and SPEC). Four weeks post-treatment, rats were killed by exsanguina-
tion under the same anaesthesia conditions as already described, and
the hearts were then collected, embedded in OCT compound (Sakura
Finetek, Torrance, CA, USA) and frozen in isopentane cooled in liquid
nitrogen.
Functional assessment
Before killing at 28 days, animals were anaesthetized by mask and
placed on the left lateral position. A single examiner evaluated left ven-
tricular function in a blinded manner by transthoracic echocardiography
equipped with a 9–11 MHz linear phase array transducer system (Acu-
sonSequoia, Siemens, Inc., Malvern, PA). Echocardiographic assess-
ments were performed on animals under anaesthesia induced by 2.5%
isoflurane at the beginning of the study in non-infarcted heart (E0),
2 weeks after induction of the myocardial infarction at the time of ran-
domization (E1) and finally 4 weeks after treatment (E2). The fraction
shortening (FS) and ejection fraction (EF) were recorded with M-mode
and 2D echocardiography. For each data point, three different heart
cycles were averaged.
Immunofluorescence
Histological analyses were performed on heart 10 lm-thick cryosec-
tions. Immunofluorescence was performed using the following primary
antibodies and dilutions: mouse anti-rat CD31 (Clone TLD-3A12; AbD
Serotec, D€usseldorf, Germany; 1:100), rabbit antimouse NG2 (Millipore,
Zug, Switzerland; 1:200), mouse anti a-smooth muscle actin (Clone
1A4; MPBiomedicals, Basel, Switzerland; 1:400), anti-human leucocyte
antigen (HLA) (Biolegend, San Diego, CA, USA; 1:200), mouse anti-
Human Nuclei (HuNu) (Millipore, Billerica, MA, USA; 1:100), goat anti-
VE-Cadherin (VE-Cad; Santa Cruz, Dallas, TX, USA; 1:100) and goat
anti-rat VEGF (R&D Systems; 1:100). Fluorescently labelled Alexa488,
Alexa546 or Alexa647 secondary antibodies (Invitrogen, Basel, Switzer-
land) were used at 1:200.
Fibrosis evaluation
Histological analyses were performed on heart cryosections stained
with Masson’s Trichrome according to standard protocols. Images
were acquired using an Olympus BX61 microscope (Olympus,
M€unster, Germany) and processed using Image J (National Institutes
of Health, Bethesda, MD, USA) by colour recognition. In all experi-
mental groups, the total amounts of fibrotic tissue (green colour) and
muscle tissue (red tone) were determined on a standardized set of
10 cross-sections, starting at the level of the papillary muscle and
moving towards the apex every 300 lm. The percentage of fibrosis
was calculated from the ratio of the green area over the total
(red + green) area.
Vessel measurements
The amount of blood vessels was quantified on images taken from
CD31-stained sections. Eighteen representative fluorescent images per
group (six images/heart and three hearts/group) were acquired with a
209 objective on an Olympus BX61 microscope (Olympus) on cross-
sections of the anterior wall taken at 300-lm intervals starting from the
level of the papillary muscle, in the area where injections were per-
formed. Blind analysis was performed with either Image J software
(National Institutes of Health) or AnalySIS D software (Soft Imaging
System, M€unster, Germany). The area fraction occupied by endothelial
cells was calculated by measuring the number of CD31-positive pixels
in each image with Image J software and normalizing it to the total
area. Alternatively, vessel length density (VLD) was quantified as previ-
ously described [21] by tracing the total length of CD31-positive vessels
in AnalySIS D software (Soft Imaging System) and dividing it by the
total area of each field.
Statistics
Data are presented as means  standard deviation and were analysed
with the statistical software Prism 5.0a (GraphPad, La Jolla, CA, USA).
For quantifications of VEGF expression, cardiac fibrosis and vasculariza-
tion, comparison between groups was performed with the non-
parametric Kruskal–Wallis test for multiple comparisons and Dunn’s
post-hoc test. All quantifications were analysed using the means of mul-
tiple individual measurements in each sample (n = number of indepen-
dent samples). Echocardiography data, which represent measurements
from the same animals before and after treatment, were analysed by
Repeated Measures ANOVA and Bonferroni post-hoc test. The normal dis-
tribution of data sets representing differences between pre- and post-
treatment (ΔEF and ΔFS) was verified and multiple comparisons were
performed with the parametric 1-way analysis of variance (ANOVA) fol-
lowed by the Bonferroni test. Differences were considered statistically
significant when P < 0.05.
Results
VEGF-producing ASC were generated by transduction with a retro-
virus carrying a bicistronic cassette that co-expresses rat VEGF164
and a truncated version of rat CD8a as a FACS-quantifiable cell sur-
face marker. The primary transduced cells were used to generate two
distinct populations. Part were FACS purified through a specific nar-
row gate, designed according to a previously published technique [9],
to produce a homogeneous cell population expressing a specific
moderate VEGF level (SPEC; Fig. 1A). The rest were sorted to elimi-
nate only non-expressing cells and generate a population heteroge-
neously expressing all the VEGF levels present after retroviral
transduction (ALL; Fig. 1A). The mesenchymal identity of the different
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ASC populations used here was previously confirmed by their robust
expression of classical mesenchymal markers (CD73, CD90, CD105)
and essentially absent expression of endothelial (CD31, CD34,
VEGFR2) or cardiac (Troponin I) markers [17]. Further, the ASC phe-
notype was not affected by retroviral transduction, FACS-sorting or
VEGF expression [17, 19]. In agreement with this, we have also previ-
ously shown that both control CD8 and ALL VEGF-expressing cells
maintained their in vitro differentiation potential towards the adi-
pogenic or osteogenic lineages compared to the na€ıve ASC [19]. In
vitro VEGF release by cells from the different groups was quantified
before in vivo injection. As shown in Fig. 1B, negative control CD8
cells, which were transduced with a retrovirus carrying only the sur-
face marker CD8, but no VEGF gene, produced negligible amounts of
rat VEGF (CD8 = 1.0  0.3 ng/106 cells/day). On the other hand,
both VEGF-expressing populations (SPEC and ALL) produced similar
total amounts of rat VEGF (ALL = 109.8  15.8 ng/106 cells/day;
SPEC = 83.1  21.1 ng/106 cells/day), in agreement with the fact
that the purified SPEC population represents the middle portion of the
levels present in the unpurified ALL population, which further com-
prises both higher and lower ones, as visible on the FACS distribution
of fluorescence intensities (Fig. 1A). On the other hand, as ASC were
of human origin, expression of the endogenous human VEGF was
also quantified. All three populations secreted very low amounts of
human VEGF165, without any difference between conditions
(CD8 = 13.8  5.2; SPEC = 15.6  6.0; and ALL = 15.3  4.8 ng/
106 cells/day). Lastly, neither the genetic modification of the cells nor
their sorting affected their morphology, which was uniformly fibrob-
last-like, typical of early-passage ASC (Fig. S1).
Surgical induction of myocardial infarction (MI) caused a moder-
ate 24-hr mortality of 15.7% (11/70 rats). To ensure a homogeneous
functional state before randomization to the different treatment
groups, 20 rats (33.8% of the surviving animals) were excluded
because the echocardiographic control after 2 weeks indicated either
a very mild or no infarction, evidenced by a left ventricular EF above
60%, or on the contrary a too severe infarction zone with a corre-
sponding EF under 45%. Therefore, a total of 39 animals weighing
252  16 grams with an EF of 45-60% were randomized into the four
treatment groups. This very selective randomization of animals with
only an ejection fraction within a narrow range was necessary to
ensure the standardization of the model and homogeneous functional
groups for comparison [20]. Mortality following the second thoraco-
tomy and the intramyocardial injection was 10.3% (4/39). No further
mortality was observed until follow-up was completed at 6 weeks.
Finally, 35 animals could be analysed in the four treatment groups:
PBS n = 7; CD8 n = 9; ALL n = 8; SPEC n = 11 (Table 1).
Controlled VEGF expression prevents cardiac
function deterioration after infarction
Cardiac functionality was assessed before infarction (E0), 2 weeks
after ligation of the LAD right before treatment (E1) and 4 weeks
post-treatment (E2) by echocardiography (Fig. 2A). On day 14, E1
echocardiography analysis showed that at the time of randomization
before treatment, the ejection fraction was significantly reduced com-
pared to the non-infarcted heart (E0) (53  6% versus 70  3%).
After randomization, all groups had a similar EF before treatment with
no statistical difference. Four weeks after treatment, EF further
decreased in the PBS (8  7%), the CD8 (6  7%) and the ALL
(13  10%) groups, but remained stable in the SPEC group
(+1  7%), (Fig. 2B–C). Interestingly, EF data suggested a statisti-
cally non-significant trend towards an even greater degree of deterio-
ration after injection of cells expressing VEGF at uncontrolled levels
(ALL) compared to PBS and control cells (CD8). Analysis of fractional
shortening showed similar results (Fig. 2D–E), with a significant
decrease between E1 and E2 for the PBS (4  3%), the CD8
(4  3%) and the ALL (7  6%) groups, but a stabilization for
the SPEC treatment group (+1  5%).
Controlled VEGF expression reduces myocardial
fibrosis
To assess the effects of the angiogenic treatment on ventricle remod-
elling, we evaluated the fraction of the left ventricular myocardium
that was substituted by a scar tissue 6 weeks after coronary ligation.
Fig. 1 Cell generation and VEGF quantification. (A) VEGF-expressing ASC were FACS-sorted to generate two populations producing either a specific
homogenous level (SPEC) or all heterogeneous levels (ALL) of VEGF. In the FACS plots: grey tinted curve = negative control; black open
curve = purified ALL cells; black tinted curve = purified SPEC cells. (B) ELISA quantification of rat VEGF production in the culture supernatants of
the different populations, expressed in ng/106 cells/day; * P < 0.05.
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Masson’s Trichrome staining of heart sections was used to detect the
high collagen content typical of fibrotic scarring (Fig. 3A, showing
representative images corresponding to the median value of each
group). In all the groups, fibrous tissue and a corresponding thinning
of the regional wall thickness substituted a significant portion of the
left ventricle. This was however greatly reduced only in the SPEC-
treated hearts. Quantification of the scar fraction (Fig. 3B) confirmed
that only controlled VEGF delivery (SPEC) could significantly reduce
fibrosis (11  5%) compared to all other groups (PBS = 27  6%;
ALL = 22  3%; CD8 = 21  3%), which were not statistically dif-
ferent from each other.
Controlled VEGF expression improves normal
myocardial angiogenesis
The quality and quantity of vascular growth induced by controlled or
heterogeneous VEGF expression were assessed by immunofluores-
cence staining 4 weeks after treatment. Both VEGF-expressing popu-
lations induced robust endothelial expansion compared to PBS or
control CD8 cells (Fig. 4A). However, vessels induced by controlled
VEGF expression (SPEC) displayed the morphology of normal and
mature capillaries, homogeneous in size and associated with typical
pericytes positive for the chondroitin sulphate proteoglycan NG2 and
negative for smooth muscle actin (SMA) expression. These were sim-
ilar in quality to the normal pre-existing vasculature visible in the PBS
and CD8 groups. A few SMA-positive vessels of regular calibre had
the morphology of arterioles feeding into the newly formed microvas-
cular networks. In contrast, heterogeneous VEGF expression by ALL
cells caused the growth of enlarged vessels, characterized by hetero-
geneous diameters, the presence of multiple lumens and a lack of
normal pericytes, substituted by a thick coat of smooth muscle cells
expressing both NG2 and SMA, similar to the progressively growing
angioma-like vascular structures previously observed in similar con-
ditions [3, 5, 17].
Quantification of the area fraction occupied by CD31-positive
endothelial cells (Fig. 4B) showed that both VEGF-expressing popula-
tions caused a significant expansion of vascular structures compared
to controls (ALL 13  5% and SPEC 9  1% versus PBS 6  1%
and CD8 6  1%). As the vessels induced by the ALL population dis-
played an irregular morphology and heterogeneous sizes, vascular
growth was independently quantified by measuring VLD, which indi-
cates the total length of vessels in a given tissue area, irrespective of
their diameter or endothelial cell content [5]. As shown in Fig. 4C, the
endothelial expansion induced by uncontrolled VEGF expression did
not translate into a corresponding increase in actual vessel length
compared to controls (ALL 11  6 mm/mm2 versus PBS 12  3
mm/mm2 and CD8 12  4 mm/mm2), whereas only the homoge-
neous VEGF-expressing population caused a significant increase in
VLD by about 60% (SPEC 17  9 mm/mm2, P < 0.01 versus all
other groups). Taken together, these data show that, although hetero-
geneous VEGF expression was efficient in inducing endothelial expan-
sion, this contributed mostly to vascular enlargement rather than the
generation of new capillary networks, which were instead efficiently
induced by controlled expression of a homogeneous-specific VEGF
level.
Cell engraftment and fate
To determine the degree of stable engraftment of the injected cells,
human ASC were tracked in harvested tissue by immunofluorescence
staining for human-specific histocompatibility antigens of class I
(HLA-class I), which are ubiquitously and specifically expressed on
human cells. Four weeks after injection, only rare human ASC were
still detectable in the rat myocardium (Fig. 5), which did not appear
integrated with the cardiomyocytes, but rather remained as isolated
single cells in between CD31-positive vessels. No differences were
observed between the three cell-based treatment groups (CD8, ALL
and SPEC), suggesting that VEGF expression did not influence the
rate of ASC survival in the myocardium. Although unlikely, it remains
theoretically possible that some injected cells may have down-
regulated HLA-class I expression in vivo. Therefore, ASC engraftment
was also analysed by in situ hybridization to the human-specific
Alu-sequence, present in the genomic DNA of all human cells. This
unrelated technique confirmed that ASC engraftment 4 weeks after
injection was very limited, without noticeable differences between the
groups (data not shown).
Lastly, we sought to determine whether engrafted ASC might con-
tribute to vessel growth by acquiring a vascular cell fate. For this pur-
pose, injected ASC were identified by staining with a human nuclei
antibody (HuNu), which is specific for human cells, and co-localized
with endothelial or pericyte markers (VE-Cadherin and NG2, respec-
tively). Most human nuclei appeared located in between vascular
structures and did not co-localize with either endothelial cells or peri-
cytes (arrows in Fig. 6) both for the control group (CD8) and the
Table 1 Overview of experimental groups.
n %
Number of animals initially included 70
Mortality post-infarction* 11 15.7
Drop-out† 20 33.8
Mortality post-treatment 4 10.2
Completed follow-up @ 6 weeks
Total 35 50.0
Phosphate-buffered saline 7
CD8 9
ALL 8
SPEC 11
*During the first 24 hrs after coronary ligation; †Criteria for a drop-
out before randomization to treatment were a left ventricular ejection
fraction (EF) >60% or <45%.
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VEGF-expressing populations (ALL and SPEC). However, the few
human cells from both VEGF-expressing populations that were pre-
sent in the myocardium 4 weeks after injection could be shown to still
produce VEGF, whereas control CD8 cells did not, as expected
(Fig. S2). Immunofluorescence staining showed that (i) the most part
of rat VEGF protein was visible in association with surviving human
cells, suggesting that endogenous VEGF is not significantly expressed
in comparison with the exogenous delivered factor; and (ii) VEGF pro-
tein was tightly associated with the surface of producing cells, with
no significant staining visible even a few lm away, providing a visual
evidence of the concept of microenvironmental localization. Because
of the essentially non-quantitative nature of immunostaining, levels of
expression by different cells could not be visualized by this technique.
Discussion
In the present study, we have provided proof-of-principle that cell-
based homogeneous expression of a specific moderate VEGF level in
post-infarction myocardium is effective to (i) induce robust growth of
normal and mature microvascular networks; (ii) prevent deterioration
of cardiac function; and (iii) limit fibrotic scarring.
Myocardial ischaemia leads to thinning of the ventricle wall, myo-
cyte slippage and ventricular dilatation, with progressive deterioration
of cardiac function until end-stage heart failure [22]. Therapeutic
angiogenesis, aiming at growing new blood vessels from pre-existing
vasculature through the delivery of exogenous factors, is an attractive
strategy to restore blood flow in the ischaemic myocardium for many
patients that cannot be treated by coronary revascularization, or as an
adjunct to surgery [23]. VEGF is the master regulator of both develop-
mental and postnatal angiogenesis [24]. However, despite promising
results obtained in various animal models of acute or progressive
ischaemia, phase I/II clinical studies based on VEGF gene therapy
failed to show evidence of benefit and conflicting outcomes were
reported for cardiac functionality after myocardial infarction [25]. Ret-
rospective analyses identified several issues underlying these nega-
tive results, including the low local transfection efficacy at safe vector
doses, resulting in limited amount and duration of protein expression
[7, 26]. VEGF gene delivery by different vectors and in a variety of tis-
sues has been shown to produce significant adverse effects, such as
vascular hyperpermeability and oedema [27], exacerbated scar tissue
formation [28], and aberrant endothelial cell proliferation with growth
of angioma-like tumours [4, 29]. Growing evidence supports the
notion that the difficulty of controlling the VEGF dose distribution in
the tissue in vivo underlies the paradox between the crucial biological
functions of VEGF and its apparent lack of a therapeutic window [8].
In fact, VEGF binds to the extracellular matrix [30] and remains local-
ized in the immediate microenvironment around each producing cell
Fig. 2 Echocardiographic cardiac function-
ality. (A) Time line of the experiment.
Three echocardiography studies were per-
formed at pre-infarction (E0), 2 weeks
after ligation of the left anterior descend-
ing but before treatment (E1) and 4 weeks
post-treatment (E2). Treatment consists in
the injection of PBS, CD8 cells or VEGF -
producing cells with controlled levels
(SPEC) or heterogenous levels (ALL).
Ejection fraction (2D-mode) in non-
infarcted hearts and pre-treatment, as well
as post-treatment per group (B) or
expressed as difference between E1 and
E2 per animal in the same group (C).
Fraction shortening (M-mode) per treat-
ment group (D), or as a difference
between E1 and E2 per animal of the
same group (E). Phosphate-buffered sal-
ine n = 7; CD8 n = 9; ALL n = 8; SPEC
n = 11; * P < 0.05, ** P < 0.01.
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in vivo [5]. While this property is crucial for the physiological function
of VEGF to guide vascular growth through the formation of gradients
in the matrix [31], it also prevents heterogeneous levels of expression
from diffusing in tissue and averaging with each other [5]. Therefore,
the challenge is to avoid that increasing delivered dose and efficacy
leads to excessive localized expression and loss of safety.
The use of stably transduced and FACS-purified ASC can over-
come this limitation, ensuring that every delivered cell produces the
same dose and therefore allowing efficient and sustained VEGF
expression without compromising safety. Controlled VEGF expression
by the SPEC cells could induce angiogenesis that was both robust,
leading to a 60% increase in vessel density, and safe, by completely
preventing the appearance of aberrant vasculature. These results are
in agreement with our previous results in healthy heart [17] and nota-
bly extend those findings to show that cell-based controlled VEGF
expression is safe even in ischaemic myocardium, where endogenous
factors are up-regulated in response to hypoxia and during the ensu-
ing inflammatory reaction.
It is interesting to note that ASC expressing heterogeneous levels
of VEGF completely failed to rescue cardiac functionality and, if at all,
showed a non-significant trend towards a worse outcome in contrac-
tility compared to no treatment. This observation is in agreement with
previous findings in skeletal muscle that uncontrolled VEGF expres-
sion failed to improve blood perfusion and induce collateral arterio-
genesis in hindlimb ischaemia [6] and likely reflects the fact that the
aberrant vascular structures induced by excessive and uncontrolled
VEGF doses behave as functional arterio-venous shunts that paradox-
ically reduce perfusion of the downstream microcirculation despite
the robust angiogenic effect [32].
The better outcomes in terms of vascularization obtained with the
SPEC population likely explain the observed reduction in fibrosis and
infarction stabilization. In fact, after both clinical and experimental MI,
unless reperfusion is performed within 6 hours, acute and permanent
coronary obstruction induces myocardial necrosis in the central
infarct zone. This acute phase occurs during the first week and is
associated with extensive inflammation and the recruitment of fibrob-
lasts. On the other hand, in the border zone of the infarction,
cardiomyocytes survive the acute injury, but are still critically under-
perfused and will eventually also die during the subsequent sub-acute
phase. This takes place up to 6 weeks after MI, is characterized by
the gradual formation of a scar, associated with a further worsening
in cardiac function and can progressively result in heart failure [20,
33]. Clinical and experimental evidence [34, 35] suggest that the
rarefaction of cardiac capillaries increases apoptosis of hypertrophied
myocytes in the peri-infarct region and promotes tissue hypoxia and
its replacement through fibrosis. The fate of the border zone myo-
cytes plays a key role in determining the sequelae of the acute MI, as
their loss will lead to scar enlargement and worsening cardiac
function, while their rescue will limit both processes. Therefore, the
improved angiogenesis induced by controlled VEGF expression,
delivered to the border zone during the early sub-acute phase of MI
remodelling (2 weeks after LAD ligation), is expected to be beneficial
by preventing cardiomyocyte death, fibrosis expansion and decline in
contractility and cardiac function over the subsequent weeks, as
shown here. A central role for cardiac angiogenesis is further
supported by findings that inhibition of new blood vessel formation
accelerates the development of left ventricular (LV) dysfunction [36],
whereas stimulation of angiogenesis improves cardiac function and
delays the onset of heart failure [37, 38]. Further, VEGF has been
demonstrated to promote several beneficial outcomes in the cardio-
vascular unit, such as recruitment and activation of cardiac progeni-
tors [39], cardiomyocyte protection from apoptosis [40] and
recruitment of bone marrow-derived mononuclear cells, which con-
tribute to the maturation of arterial walls [41].
The observed very limited engraftment of human ASC 4 weeks
after intramyocardial injection is in agreement with the previous
reports [42] and has been attributed to two distinct events. First, the
cell transfer is inefficient because of cell losses as a result of leakage
through trans-epicardial puncture holes, wash-out through the
venous system or squeezing of cells by the heartbeats. Second, many
of the originally injected cells die because of ischaemia of the target
areas and apoptosis subsequent to the loss of cell anchorage to
matrix [42].
Interestingly, newly induced vessels persisted in the injection
areas despite the low engraftment of implanted cells, while results in
different tissues have shown that approximately 4 weeks of sustained
VEGF expression are required before new vessels stabilize and can
persist independently of further stimulation [5, 43]. It is unlikely that
this may reflect tissue-specific differences in the stabilization kinetics
of myocardial vessels, as experiments with conditional switching of
VEGF expression showed that newly induced cardiac microvessels
are still unstable after 2 weeks, but persist after 4 weeks [43]. On the
other hand, ASC have been described to secrete cytokines involved in
vascular stabilization, such as transforming growth factor-b1 (TGF-
b1) and basic fibroblast growth factor [44]. Interestingly, we have
recently identified a pericyte-independent mechanism for vascular
Fig. 3 Fibrosis quantification. (A) Representative cryosections stained
with Masson’s Trichrome for the four treatment groups, corresponding
to the median value of the quantification. (B) Fibrosis quantification
measured in the percentage of green pixels over the total coloured pixel
numbers for all treatment groups (CD8 and Phosphate-buffered saline
n = 3; ALL and SPEC n = 4); * P < 0.05, ** P < 0.01.
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stabilization, whereby a specific subset of circulating monocytes
expressing the VEGF co-receptor Neuropilin-1 (NEM) are recruited to
sites of VEGF-induced angiogenesis by the axon-guidance factor
Semaphorin3A and accelerate stabilization of newly formed vessels
by activating endothelial TGF-b1 signalling [45]. Whether ASC may
produce Semaphorin 3A and contribute to NEM recruitment remains
to be investigated.
ASC can also produce angiogenic and antiapoptotic paracrine
factors that contribute to cardioprotection [46]. However, the find-
ings reported here show that only VEGF overexpression at
Fig. 4Myocardial angiogenesis. (A) Immunofluorescence staining for endothelium (CD31, in red), pericytes (NG2, in green), smooth muscle cells
(SMA, in cyan) and nuclei (DAPI, in blue) in sections of myocardium injected with phosphate-buffered saline, control cells (CD8) or ASC expressing
uncontrolled heterogeneous levels (ALL) or a specific homogeneous VEGF level (SPEC). Angiogenesis was quantified either as the area fraction
occupied by CD31-positive pixels (B) or as vessel length density (C); n = 3 per group; * P < 0.05, ** P < 0.01.
8 ª 2018 The Authors.
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controlled levels by the SPEC population induced efficient and nor-
mal angiogenesis with functional benefit on cardiac function,
whereas ASC alone did not cause any improvement compared to
PBS injection, nor did any ASC population directly take part in
new vessel formation as endothelial or mural cells. These controls
support the conclusion that the observed functional improvements
could be ascribed prevalently to the direct angiogenic effects of
VEGF delivery.
The findings reported here provide proof-of-principle for the
therapeutic potential of controlling the distribution of VEGF expres-
sion levels in the myocardium. The outcome of preventing further
decline in cardiac functionality and therefore avoiding progression
towards heart failure is consistent with the histological correlate
of limiting the extension of fibrotic scar and is in agreement with
other pre-clinical results obtained in the same small rodent model
of acute infarction, recently reviewed in a meta-analysis by Kane-
lidis et al. [47].
In view of a potential clinical translation, the use of retrovi-
ral vectors raises some safety concerns because of the possible
neoplastic transformation of transduced stem cells by insertional
mutagenesis [48]. However, the same approach is readily appli-
cable to progenitors transduced with clinically compliant new-
generation vectors, such as self-inactivating lentiviruses with
chromatin insulator elements that ensure stable and sustained
transgene expression in the absence of oncogenic potential
[49].
In conclusion, we obtained functional evidence that controlled
VEGF expression by transduced and FACS-purified ASC is safe
and effective in inducing robust growth of uniformly normal
blood vessels in ischaemic myocardium, preventing the loss of
cardiac functionality and reducing heart fibrosis after myocardial
infarction. These results suggest that this cell-based gene delivery
approach, by affording precise control over the distribution of
expression levels in vivo, could help overcome a significant
Fig. 5 Cell engraftment. Survival of human ASC was assessed by immunostaining for (HLA)-Class I (red), while endothelium was detected by CD31
expression (green), and nuclei by DAPI staining (blue) 4 weeks after injection of phosphate-buffered saline, control cells (CD8) or the two VEGF -
expressing populations (ALL and SPEC). White arrows indicate single engrafted human cells.
ª 2018 The Authors.
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obstacle towards safe and effective therapeutic angiogenesis in
the heart.
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Figure S1 Cell morphology. Before in vivo injection, cell morphology
was assessed by fluorescence microscopy after in vitro staining
for cell surface CD8a expression for control cells (CD8) or the two
VEGF-expressing populations (ALL and SPEC). Size bar: left
column = 500 lm, right column = 50 lm.
Figure S2 VEGF production. Production of rat VEGF by the injected
human cells (control cells CD8; VEGF-producing cells ALL and SPEC)
after 4 weeks in vivo assessed by immunostaining for rat VEGF (rVEGF,
in red), human nuclei (HuNu, in green) and nuclei by DAPI staining (blue).
Fig. 6 Cell fate. Fate of human ASC was
assessed by immunostaining for the
endothelial junctional marker VE-Cadherin
(VE-Cad, in red), pericytes (NG2, in
white), human nuclei (HuNu, in green)
and nuclei by DAPI staining (blue)
4 weeks after injection of control cells
(CD8) or ASC expressing uncontrolled
heterogeneous levels (ALL) or a specific
homogeneous VEGF level (SPEC).
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